Tags

Type your tag names separated by a space and hit enter

Cannabidiol for the treatment of psychosis in Parkinson's disease.
J Psychopharmacol. 2009 Nov; 23(8):979-83.JP

Abstract

The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.

Authors+Show Affiliations

Department of Neuropsychiatry and Medical Psychology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. awzuardi@fmrp.usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18801821

Citation

Zuardi, A W., et al. "Cannabidiol for the Treatment of Psychosis in Parkinson's Disease." Journal of Psychopharmacology (Oxford, England), vol. 23, no. 8, 2009, pp. 979-83.
Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009;23(8):979-83.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., Dursun, S. M., & Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology (Oxford, England), 23(8), 979-83. https://doi.org/10.1177/0269881108096519
Zuardi AW, et al. Cannabidiol for the Treatment of Psychosis in Parkinson's Disease. J Psychopharmacol. 2009;23(8):979-83. PubMed PMID: 18801821.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol for the treatment of psychosis in Parkinson's disease. AU - Zuardi,A W, AU - Crippa,J A S, AU - Hallak,J E C, AU - Pinto,J P, AU - Chagas,M H N, AU - Rodrigues,G G R, AU - Dursun,S M, AU - Tumas,V, Y1 - 2008/09/18/ PY - 2008/9/20/pubmed PY - 2010/1/13/medline PY - 2008/9/20/entrez SP - 979 EP - 83 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 23 IS - 8 N2 - The management of psychosis in Parkinson's disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective effect of Cannabidiol (CBD) has been suggested. Therefore, the aim of the present study was to directly evaluate for the first time, the efficacy, tolerability and safety of CBD on PD patients with psychotic symptoms. This was an open-label pilot study. Six consecutive outpatients (four men and two women) with the diagnosis of PD and who had psychosis for at least 3 months were selected for the study. All patients received CBD in flexible dose (started with an oral dose of 150 mg/day) for 4 weeks, in addition to their usual therapy. The psychotic symptoms evaluated by the Brief Psychiatric Rating Scale and the Parkinson Psychosis Questionnaire showed a significant decrease under CBD treatment. CBD did not worsen the motor function and decreased the total scores of the Unified Parkinson's Disease Rating Scale. No adverse effect was observed during the treatment. These preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/18801821/Cannabidiol_for_the_treatment_of_psychosis_in_Parkinson's_disease_ L2 - https://journals.sagepub.com/doi/10.1177/0269881108096519?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -